Immunohistochemical assessment and prognostic value of hepatitis B virus X protein in chronic hepatitis and primary hepatocellular carcinomas usinganti-HBxAg monoclonal antibody

2001 ◽  
Vol 7 (3) ◽  
pp. 178-184 ◽  
Author(s):  
József Pál ◽  
Csilla Somogyi ◽  
Ágnes Szmolenszky ◽  
György Szekeres ◽  
József Sípos ◽  
...  
2010 ◽  
Vol 4 (4) ◽  
pp. 399-411 ◽  
Author(s):  
Lei Chen ◽  
Liang Hu ◽  
Liang Li ◽  
Yuan Liu ◽  
Qian-Qian Tu ◽  
...  

2014 ◽  
Vol 159 (10) ◽  
pp. 2731-2735 ◽  
Author(s):  
Lili Wei ◽  
Zhongliang Shen ◽  
Xue Zhao ◽  
Yanxin Wu ◽  
Wei Liu ◽  
...  

2019 ◽  
Vol 37 (3) ◽  
pp. 387-392
Author(s):  
Monika Mani ◽  
Shanthi Vijayaraghavan ◽  
Gopalsamy Sarangan ◽  
Ramya Barani ◽  
Priya Abraham ◽  
...  

Hybridoma ◽  
2000 ◽  
Vol 19 (1) ◽  
pp. 73-80 ◽  
Author(s):  
Og Yi Park ◽  
Young Hee Jin ◽  
Millina Lee ◽  
Ho-Joon Shin ◽  
Hyung-Il Kim ◽  
...  

2009 ◽  
Vol 2009 ◽  
pp. 1-6 ◽  
Author(s):  
Hang Zhang ◽  
Lian-Ying Wu ◽  
Shuai Zhang ◽  
Li-Yan Qiu ◽  
Nan Li ◽  
...  

Hepatitis B virus X protein (HBx) plays a crucial role in the development of hepatocellular carcinoma (HCC). However, the significance of circulating antibody to hepatitis B virus X antigen (anti-HBx) in sera remains unclear. In the present study, we examined the titers of anti-HBx (IgG) in the sera from 173 patients with chronic hepatitis B (CHB), 106 liver cirrhosis (LC), and 61 HCC by enzyme-linked immunosorbent assay (ELISA), respectively. Our data showed that the positive rates of anti-HBx were higher in sera of LC (40.6%) and HCC (34.4%) than those of CHB (10.4%),P<.05. In all 40 patients with anti-HBx+ out of 340 patients, 39 (97.5%) were HBsAg/HBeAg/anti-HBc+ and 1 (2.5%) was anti-HBs+ (P<.01), suggesting that anti-HBx in sera is a marker of HBV replication rather than a protective antibody. Thus, our findings reveal that circulating anti-HBx in sera is one of the markers of development of LC and HCC mediated by HBV.


Sign in / Sign up

Export Citation Format

Share Document